Similarly, for the treatment of non-Hodgkin lymphoma, the CD37-targeting antibody [212Pb]Pb-NNV003 showed survival benefits in immunocompromised MEC-2 and Daudi tumor models, though biodistribution revealed rapid uptake in some healthy tissues and slow tumor uptake 84​. The gene discussed is CD37; the disease is neoplasm.